Web Analytics

3 Latest Announced Rounds

$1,415.00M Raised in 37 Funding Rounds in the past 7 Days - View All

Funding Round Profile

RheumaGen

start up
United States - Denver, Colorado
  • 10/01/2025
  • Series A
  • $15,000,000

RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure major autoimmune diseases at their source. RheumaGen focuses on editing the human leukocyte antigen (HLA), or “immune gene,” to develop one-time, curative cell and gene therapies. RheumaGen is headquartered in Aurora, Colorado. For more information, please visit rheumagen.com.


Related People

Richard FreedFounder

Richard Freed United States - Denver, Colorado

Co-Founder, CEO, Husband, Dad